Electrospun Polycaprolactone (PCL)/Microbial Chondroitin Sulfate (CS)-Based Transdermal Patches for Optimized Ribociclib Delivery

Basit Öğe Kaydı
dc.authoridBALCIOGLU, SEVGI/0000-0003-0724-4772
dc.contributor.authorGunduz Tavlar, Nermin
dc.contributor.authorBalcioglu, Sevgi
dc.contributor.authorErenler, Ayse Sebnem
dc.contributor.authorAtes, Burhan
dc.date.accessioned2025-10-24T18:09:12Z
dc.date.available2025-10-24T18:09:12Z
dc.date.issued2025
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractBreast cancer remains the most prevalent cancer worldwide and a leading cause of mortality in women, demanding advanced drug delivery strategies. Ribociclib, a CDK4/6 inhibitor used in hormone-dependent breast cancer therapy, is effective but requires high oral doses, leading to severe systemic toxicity. To overcome this limitation, we developed electrospun PCL/CS-based transdermal patches designed to enhance drug bioavailability, prolong half-life, and minimize side effects. Extensive characterization confirmed the structural integrity and performance of the patches, demonstrating high swelling capacity (81-93%), superior thickness uniformity (95-100%), and exceptional folding endurance (1000-1540 cycles). The patches exhibited excellent weight homogeneity (92-99%) for consistent drug distribution, while adhesion strength (144-386 kPa) ensured stable skin attachment. HPLC analysis revealed sustained Ribociclib release (similar to 95% over 48 h), and ex vivo rat skin diffusion studies confirmed high permeability (68-81%), indicating effective transdermal absorption. Drug retention efficiency exceeded 95% in both the reservoir and drug release layers. Biocompatibility assessments with L-929 fibroblasts demonstrated excellent cell viability (90-95%), while MCF-7 breast cancer cells exhibited potent cytotoxicity (93-94%), comparable to standard Ribociclib treatment. Despite the therapeutic potential of transdermal drug delivery systems (TDDS), Ribociclib has been scarcely explored in this context. This study pioneers a promising alternative for controlled, sustained drug release, potentially revolutionizing breast cancer treatment by improving patient compliance, reducing systemic toxicity, and enhancing therapeutic outcomes.
dc.description.sponsorshipIn?n? ?niversitesi [222Z300]; Scientific and Technological Research Council of Turkiye (TUBITAK) [FYL-2023-3196]; Inonu University
dc.description.sponsorshipThis work was supported financially by the Scientific and Technological Research Council of Turkiye (TUBITAK) (Project No. 222Z300) and Inonu University (Project No. FYL-2023-3196).
dc.identifier.doi10.1021/acsapm.5c01134
dc.identifier.endpage9680
dc.identifier.issn2637-6105
dc.identifier.issue15
dc.identifier.startpage9669
dc.identifier.urihttps://doi.org/10.1021/acsapm.5c01134
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3511
dc.identifier.volume7
dc.identifier.wosWOS:001532268000001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherAmer Chemical Soc
dc.relation.ispartofAcs Applied Polymer Materials
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20251023
dc.subjectbreast cancer; transdermal patch; Ribociclib; electrospinning; biocompatibility
dc.titleElectrospun Polycaprolactone (PCL)/Microbial Chondroitin Sulfate (CS)-Based Transdermal Patches for Optimized Ribociclib Delivery
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu